Healthcare PharmaceuticalsNuvaxovid
Owned by Novavax, Inc.
Novavax's protein-based COVID-19 vaccine using recombinant nanoparticle technology and Matrix-M adjuvant, FDA emergency use authorized July 13, 2022, with a biologics license application (BLA) approved May 19, 2025, offering a protein subunit alternative to mRNA-based COVID-19 vaccines for adults and adolescents.
vaccinecovid-19protein-subunit